Serum Genetic Markers as Surrogates of Prostate Cancer Progression
Abstract
The main purpose of the proposal is that detection of free tumor-related DNA marker(s) in serum can be used as surrogate genetic markers for monitoring ongoing events related to the pathogenesis of metastasis and provide prognostic insight into disease outcome and treatment response. The scope of the studies is to develop and validate tumor-related circulating DNA in serum of prostate cancer (PCA) patients. The goal is to validate these DNA markers. We have developed assays for circulating serum DNA in prostate cancer patients (PCA). The program has gotten on track in the past year since the approval of the Human subjects IRB. PCA patient s and normal donor serum was accrued in the past year. We have been screening for new circulating methylated and unmethylated tumor-related DNA markers. Several DNA markers were found to correlate with PCA stage significantly. Highly sensitive assays were developed to detect these DNA markers in serum. Optimal conditions to obtain high specificity and sensitivity were determined. In the coming year more PCA patients will be accrued as well as further accrual of normal age-matched donors for the study. Assays for the markers will be carried out. We plan to complete the study in the upcoming year.
Document Details
- Document Type
- Technical Report
- Publication Date
- Apr 01, 2007
- Accession Number
- ADA474608
Entities
People
- Dave S. Hoon